Amycretin Explained

Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.[1] [2] [3] [4] [5]

Initial trials

On 7 March 2024, Novo Nordisk announced the results from the Phase I trial of the pill form of Amycretin showed participants lost 13.1% of their weight after 12 weeks. For comparison, clinical trials for the older drug Wegovy which was also developed by Novo Nordisk indicated weight loss of 6% after 12 weeks and 15% after 68 weeks.[6]

Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecasts the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.

Notes and References

  1. Melson . Eka . Ashraf . Uzma . Papamargaritis . Dimitris . Davies . Melanie J. . What is the pipeline for future medications for obesity? . International Journal of Obesity . 1 February 2024 . 1–19 . 10.1038/s41366-024-01473-y . en . 1476-5497. free .
  2. News: Linnane . Ciara . Viking Therapeutics faces higher bar for oral weight-loss drug . 11 March 2024 . MarketWatch . EN-US.
  3. Jamaluddin . Aqfan . Gorvin . Caroline M . RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis . Journal of Molecular Endocrinology . Bioscientifica . 70 . 4 . 2023-03-21 . 0952-5041 . 10.1530/jme-23-0014 . 10160555 .
  4. Goldenberg . Ronald M. . Gilbert . Jeremy D. . Manjoo . Priya . Pedersen . Sue D. . Woo . Vincent C. . Lovshin . Julie A. . Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists . Obesity Reviews . 25 . 3 . 2024 . 1467-7881 . 10.1111/obr.13663 .
  5. Goldenberg . Ronald M. . Gilbert . Jeremy D. . Manjoo . Priya . Pedersen . Sue D. . Woo . Vincent C. . Lovshin . Julie A. . Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists . Obesity Reviews . March 2024 . 25 . 3 . 10.1111/obr.13663.
  6. Web site: "Novo valuation surpasses Tesla on experimental obesity drug data" . March 7, 2024 . Reuters . 2024-03-13.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amycretin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.